Excellent R&D experts in Cell2in seek to develop
innovative cell therapy and future medical technology

We aim to become the global biotech company
based on proprietary technology.

R&D based company with mass cell culture technology and cell quality management technology

Patented in countries
leading new drug development market

Enter the global biotech market
with Proprietary technology

Intellectual Property

Cell2in is committed to protect our core technology by establishment of intellectual property in the field of cell therapy

Name of Technology Country of Application Application and Registration No. Applied and Registered Date
Real-time Imaging Sensor for Measuring Cellular Thiol Levels Korea 10-1862581 2018. 05. 24
United States 10.215.757B2 2019. 02. 26
Korea 10-1983803 2019. 05. 23
United States 10.620.215 2020. 04. 14
Real-time Fluorescence Imaging Sensor for Estimating the Glutathione in Cellular Organelle and Manufacturing Method Thereof Korea 10-2133794 2020. 07. 08
Canada (application) 3.072.434 2020. 02. 07
Australia (application) 2018320601 2020. 02. 19
United States (application) 16/640717 2020. 02. 20
Europe (application) 18848372.1 2020. 02. 21
China (application) 201880054675.0 2020. 02. 21
India (application) 202017007994 2020. 02. 25
Japan (application) 2020-511502 2020. 02. 19
Real-time Fluorescence Imaging Sensor for Estimating the Glutathione in Endoplasmic Reticulum and a Method of Using It Korea 10-2019-0178260 2019. 12. 30

Gene Biomarker

Name of Technology Country of Application Application and Registration No. Applied and Registered Date
FreSHtracer-based Application of the Genetic Profile of Separated Cells PCT PCT/KR 2018/008239 2018. 07. 20

Stem Cell Therapy

Name of Technology Country of Application Application and Registration No. Applied and Registered Date
Composite for Treatment of Thrombocytopenia Korea 10-2021-0063975 2021. 05. 18
Gene Market for Evaluating the Characteristics of Stem Cells and the Use of the Same Korea 10-2020-0180455 2020. 12. 22

Cell Quality Control

Name of Technology Country of Application Application and Registration No. Applied and Registered Date
Method of Therapeutic Cell Quality Improvement Based on Real-time Glutathione Measurement Korea 10-2119714 2020. 06. 01
Europe (application) 18883520.1 2020. 05. 27
China (application) 201880077266.2 2020. 05. 28
Japan (application) 2020-546264 2020. 05. 27
United States (application) 16/767985 2020. 05. 28
Method of Therapeutic Cell Quality Measurement Based on Real-time Glutathione Measurement Korea 10-2145929 2020. 08. 12
United States (application) 16/768014 2020. 05. 28
Europe (application) 18884812.1 2020. 05. 27
China (application) 201880077236.1 2020. 05. 28
Japan (application) 2020-546265 2020. 05. 27

Publication

Cell2in has continuously published its research results through famous academic societies and journals.

Development Technology and mesenchymal stem cells : Lim et al., Glutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for graft-versus-host disease via CREB1-NRF2 pathway, Science Advances (2020), 6

Glutathione (GSH), the most abundant nonprotein thiol functioning as an antioxidant, plays critical roles in maintaining
the core functions of mesenchymal stem cells (MSCs), which are used as a cellular immunotherapy for
graft-versus-host disease (GVHD). However, the role of GSH dynamics in MSCs remains elusive. Genome-wide
gene
expression profiling and high-throughput live-cell imaging assays revealed that CREB1 enforced the GSH-recovering
capacity (GRC) of MSCs through NRF2 by directly up-regulating NRF2 target genes responsible for GSH synthesis
and redox cycling. MSCs with enhanced GSH levels and GRC mediated by CREB1-NRF2 have improved
self-renewal, migratory, anti-inflammatory, and T cell suppression capacities. Administration of MSCs overexpressing
CREB1-NRF2 target genes alleviated GVHD in a humanized mouse model, resulting in improved survival,
decreased weight loss, and reduced histopathologic damages in GVHD target organs. Collectively, these findings
demonstrate the molecular and functional importance of the CREB1-NRF2 pathway in maintaining MSC GSH dynamics,
determining therapeutic outcomes for GVHD treatment.